Related Experiment Videos
CD28 mRNA rapidly decays when activated T cells are functionally anergized with specific peptide
R A Lake1, R E O'Hehir, A Verhoef
1Department of Immunology, St Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London, UK.
International Immunology
|May 1, 1993
Summary
Inducing T cell anergy, a state of non-responsiveness, can reverse immune diseases. Researchers found that both resting and activated T cells can become anergic, marked by CD28 downregulation, offering new therapeutic strategies.
Area of Science:
- Immunology
- Cellular Biology
- Molecular Medicine
Background:
- Immunologically mediated diseases may be reversed by inducing T cell non-responsiveness.
- Understanding T cell anergy mechanisms is crucial for therapeutic development.
Purpose of the Study:
- To investigate the mechanisms of T cell anergy induction in vitro.
- To determine if activated T cells can be rendered non-responsive.
- To identify molecular changes associated with T cell anergy.
Main Methods:
- Functional inactivation of cloned T cells in vitro using high-dose peptide.
- Analysis of surface phenotype modulation during anergy induction.
- Assessment of CD28 expression at mRNA and protein levels.
Main Results:
- Resting T cells can be functionally inactivated by high peptide doses.
- T cell receptor expression decreases, while CD2 and CD25 increase during anergy.
- Activated T cells, like resting cells, can be rendered non-responsive.
- Anergy induction in activated T cells involves significant CD28 downregulation.
Conclusions:
- T cell anergy can be induced in both resting and activated states.
- Downregulation of CD28 is a key feature of T cell anergy.
- These findings support clinical strategies targeting activated T cells in immune diseases.